Technologies du CNRS

Trouvez les meilleures technologies du CNRS pour mener à bien votre projet d’innovation.

Les brevets les plus récents

Vous êtes un chercheur ?

Nous pouvons vous accompagner sur toute votre
démarche de transfert de technologies.

Voir tous nos services

Vous êtes un industriel ?

Grâce à notre expérience, nos réseaux et notre connaissance de l’écosystème de l’innovation nous vous accompagnons tout au long de votre projet.

Nous contacter

Découvrez les technologies du CNRS

Voir nos actualités et rendez-vous

Rencontrez l’équipe

Fermer

Silica-based nanoparticles targeting cancer cell for photodynamic therapy

Référence

02212-01

Statut des brevets

Priority patent application FR0805034 filed on September 15, 2008 entitled « Dérivés de métalloporphyrines, nanoparticules les comprenant »

Inventeurs

David BREVET
Ouhiba HOCINE
Jean-Olivier DURAND
Philippe MAILLARD
Alain MORERE
Marcel GARCIA
Monique SMAIHI
Magali GARY-BOBO

Statut commercial

Exclusive or non-exclusive licenses

Laboratoire

Institut Charles Gerhardt, Institut de Chimie Moléculaire et des Matériaux de Montpellier (UMR 5253), Montpellier, France, http://www.icgm.fr

Description

CONTEXT

Photodynamic therapy (PDT) is an emerging modality for the treatment of a variety of oncological, cardiovascular, dermatological and ophthalmic diseases. In PDT, irradiated photosentisizers that surround or enter cells transfer their energy to molecular oxygen, thus forming highly reactive singlet oxygen (1O2) and other reactive oxygen species which, in turn, kill the nearby cells. This invention related to nanovectors which jointly ensure cancer cells targeting and two-photon imaging as well as their mono or biphotonic photodynamic therapy (PDT).

TECHNICAL DESCRIPTION

The vectors are silica-based nanoparticles that encapsulate fluorescent photosensitizers. The confinement of a photosensitizer in a solid matrix allow its use in biological environments. The photosensitizers are enable, by mean of biphotonic excitation, a high resolution cancer cells imaging. A singlet oxygen production inside the cells are assured by mono or biphotonic excitation.

BENEFITS

Nanoparticules are biocompatible, biodegradable, and highly specific. With this technology, PDT side effects are reduced thanks to a cell targeting. Moreover, irradiations at near infrared light confer a better tissue penetration leading to improved treatment efficiency. PDT also offers a lot of advantages such as minimally invasive and minimally toxic therapy. Furthermore, PDT is non mutagenic compared to radio or chemotherapy which is an advantage for cancers such as retinoblastoma. Comparing current treatment of cancers, PDT is much cheaper alternative. Moreover, for patient, PDT post-operative recovery is better requiring hours or days rather than weeks.

INDUSTRIAL APPLICATIONS

Treatment of a wide variety of solid cancers, including deep tissue and multisite cancers.
Treatment of a variety of dermatologic conditions, including actinic keratoses, photoaging and other cutaneous concerns.

DEVELOPMENT STAGE

The PDT treatments are under study in vivo with mice bearing xenografted tumors. Preliminary experiments with two-photon PDT on mice with colon cancer showed a reduction of 70% of the tumor mass.

For further information, please contact us (Ref 02212-01)

 


Besoin de plus d'informations ?

Nous contacter
Fermer

Contactez-nous

  • Ce champ n’est utilisé qu’à des fins de validation et devrait rester inchangé.
Fermer

Les brevets les plus récents